STARTUPS, BIOTECH - VaxInnate keeps slowly raising capital for seasonal flu vaccine
http://medcitynews.com/2015/09/vaxinnate-keeps-slowly-raising-capital-for-seasonal-flu-vaccine/
STARTUPS, BIOTECH
VaxInnate keeps slowly raising capital for seasonal flu vaccine
By MEGHANA KESHAVAN
Sep 29, 2015 at 3:50 PM
New Jersey startup VaxInnate keeps slowly raising capital as it moves forward in clinical trials for a new flu vaccine. The company has raised $3.3 million of a proposed $4.3 million equity round, according to an SEC filing.
On top of that, VaxInnate has a contract set up with BARDA for up to $53 million in non-dilutive funding to develop a seasonal and pandemic influenza vaccine. Last year, it also raised $6 million in equity.
The company launched a Phase 2 study of its VAX2012Q seasonal influenza vaccine this past June, and expects top-line results soon, it said in a release. Its made up of four strains of the virus that are each fused to a flagellin protein, which acts like a toll-like receptor ligand. These tend to activate the immune system. In Phase 1 studies, a low dosage of the vaccine showed immunogenic effects, VaxInnate says.
MANDATES! MANDATES! YEAH!
Oops, sorry, that's not my view.